BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 30179749)

  • 1. HDAC3 is a potential validated target for cancer: An overview on the benzamide-based selective HDAC3 inhibitors through comparative SAR/QSAR/QAAR approaches.
    Adhikari N; Amin SA; Trivedi P; Jha T; Ghosh B
    Eur J Med Chem; 2018 Sep; 157():1127-1142. PubMed ID: 30179749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, biological evaluation, and molecular docking analysis of novel linker-less benzamide based potent and selective HDAC3 inhibitors.
    Routholla G; Pulya S; Patel T; Abdul Amin S; Adhikari N; Biswas S; Jha T; Ghosh B
    Bioorg Chem; 2021 Sep; 114():105050. PubMed ID: 34120025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Designing potential HDAC3 inhibitors to improve memory and learning.
    Amin SA; Adhikari N; Jha T; Ghosh B
    J Biomol Struct Dyn; 2019 May; 37(8):2133-2142. PubMed ID: 30044204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and binding mode of interaction of novel small molecule o-hydroxy benzamides as HDAC3-selective inhibitors with promising antitumor effects in 4T1-Luc breast cancer xenograft model.
    Routholla G; Pulya S; Patel T; Adhikari N; Abdul Amin S; Paul M; Bhagavatula S; Biswas S; Jha T; Ghosh B
    Bioorg Chem; 2021 Dec; 117():105446. PubMed ID: 34717237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3D-QSAR (CoMFA, CoMSIA) and Molecular Docking Studies on Histone Deacetylase 1 Selective Inhibitors.
    Abdizadeh T; Ghodsi R; Hadizadeh F
    Recent Pat Anticancer Drug Discov; 2017 Nov; 12(4):365-383. PubMed ID: 28482791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent and Selective Inhibitors of Histone Deacetylase-3 Containing Chiral Oxazoline Capping Groups and a N-(2-Aminophenyl)-benzamide Binding Unit.
    Marson CM; Matthews CJ; Atkinson SJ; Lamadema N; Thomas NS
    J Med Chem; 2015 Sep; 58(17):6803-18. PubMed ID: 26287310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase 3 inhibitors in learning and memory processes with special emphasis on benzamides.
    Amin SA; Adhikari N; Kotagiri S; Jha T; Ghosh B
    Eur J Med Chem; 2019 Mar; 166():369-380. PubMed ID: 30735902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of potent, isoform-selective inhibitors of histone deacetylase containing chiral heterocyclic capping groups and a N-(2-aminophenyl)benzamide binding unit.
    Marson CM; Matthews CJ; Yiannaki E; Atkinson SJ; Soden PE; Shukla L; Lamadema N; Thomas NS
    J Med Chem; 2013 Aug; 56(15):6156-74. PubMed ID: 23829483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.
    Li X; Zhang Y; Jiang Y; Wu J; Inks ES; Chou CJ; Gao S; Hou J; Ding Q; Li J; Wang X; Huang Y; Xu W
    Eur J Med Chem; 2017 Jul; 134():185-206. PubMed ID: 28415009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacophore-based virtual screening, 3D QSAR, Docking, ADMET, and MD simulation studies: An in silico perspective for the identification of new potential HDAC3 inhibitors.
    Lanka G; Begum D; Banerjee S; Adhikari N; P Y; Ghosh B
    Comput Biol Med; 2023 Nov; 166():107481. PubMed ID: 37741229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review.
    Sarkar R; Banerjee S; Amin SA; Adhikari N; Jha T
    Eur J Med Chem; 2020 Apr; 192():112171. PubMed ID: 32163814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ligand release mechanisms and channels in histone deacetylases.
    Kalyaanamoorthy S; Chen YP
    J Comput Chem; 2013 Oct; 34(26):2270-83. PubMed ID: 23893931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diverse classes of HDAC8 inhibitors: in search of molecular fingerprints that regulate activity.
    Amin SA; Adhikari N; Jha T
    Future Med Chem; 2018 Jul; 10(13):1589-1602. PubMed ID: 29953251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2).
    Methot JL; Hamblett CL; Mampreian DM; Jung J; Harsch A; Szewczak AA; Dahlberg WK; Middleton RE; Hughes B; Fleming JC; Wang H; Kral AM; Ozerova N; Cruz JC; Haines B; Chenard M; Kenific CM; Secrist JP; Miller TA
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6104-9. PubMed ID: 18951790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MS-275 inhibits aroclor 1254-induced SH-SY5Y neuronal cell toxicity by preventing the formation of the HDAC3/REST complex on the synapsin-1 promoter.
    Formisano L; Guida N; Laudati G; Mascolo L; Di Renzo G; Canzoniero LM
    J Pharmacol Exp Ther; 2015 Feb; 352(2):236-43. PubMed ID: 25467131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dissecting Histone Deacetylase 3 in Multiple Disease Conditions: Selective Inhibition as a Promising Therapeutic Strategy.
    Adhikari N; Jha T; Ghosh B
    J Med Chem; 2021 Jul; 64(13):8827-8869. PubMed ID: 34161101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2).
    Methot JL; Chakravarty PK; Chenard M; Close J; Cruz JC; Dahlberg WK; Fleming J; Hamblett CL; Hamill JE; Harrington P; Harsch A; Heidebrecht R; Hughes B; Jung J; Kenific CM; Kral AM; Meinke PT; Middleton RE; Ozerova N; Sloman DL; Stanton MG; Szewczak AA; Tyagarajan S; Witter DJ; Secrist JP; Miller TA
    Bioorg Med Chem Lett; 2008 Feb; 18(3):973-8. PubMed ID: 18182289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3D QSAR of aminophenyl benzamide derivatives as histone deacetylase inhibitors.
    Mahipal ; Tanwar OP; Karthikeyan C; Moorthy NS; Trivedi P
    Med Chem; 2010 Sep; 6(5):277-85. PubMed ID: 20977417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and docking studies on benzamide derivatives as histone deacetylase inhibitors.
    Lu A; Luo H; Shi M; Wu G; Yuan Y; Liu J; Tang F
    Bioorg Med Chem Lett; 2011 Aug; 21(16):4924-7. PubMed ID: 21741834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of differentiation and apoptosis in leukaemic cell lines by the novel benzamide family histone deacetylase 2 and 3 inhibitor MI-192.
    Boissinot M; Inman M; Hempshall A; James SR; Gill JH; Selby P; Bowen DT; Grigg R; Cockerill PN
    Leuk Res; 2012 Oct; 36(10):1304-10. PubMed ID: 22818799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.